Healthcare News

Allogenetics today announced the appointment of Jeroen Rovers, MD, PhD, as Chief Medical Officer.

Company announcement no. 26 - 2621 July 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as...

Enterome Phase 2 data show EO2463-induced CD8 T-cell expansion correlates with PFS in patients with iNHL in the watch-and-wait setting

OMEICOS has successfully completed the End-of-Phase 2 (EOP2) meeting with the U.S. FDA enabling a pivotal study in Primary Mitochondrial Disease (PMD).

Validation du procédé de biorecyclage « fibre-à-fibre », dans des conditions représentatives d’une exploitation industrielle100ème batch1 produit avec succès au sein du démonstrateur de...

Validation of the "Fiber-to-Fiber" biorecycling process under conditions representative of industrial operations100th batch1 successfully produced at the Clermont-Ferrand demonstration plantMore...

Ad-hoc-Mitteilung gemäss Art. 53 KRZweites QuartalDer Nettoumsatz stieg um +1% (kWk1, +3% USD), das operative Kernergebnis1 blieb unverändert (kWk und USD)Das Umsatzwachstum beruhte auf den...

Ad hoc announcement pursuant to Art. 53 LRSecond quarterNet sales grew +1% (cc1, +3% USD), with core operating income1 flat (cc and USD)Sales growth driven by priority brands including Kisqali (+43%...

MELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides a market update on its commercial and operational...

First patient dosed in Phase 3 LUTEON1 trial evaluating TLX250-Tx in relapsed or recurrent clear cell renal cell carcinoma (ccRCC).LUTEON is the first Phase 3 study of a CAIX2-targeted...